LobbyingTechimmune lobbying by quarter
Techimmune's latest lobbying report covers Q4 2023, at $30K. Its first report covers Q2 2023; the issues it reports most are Health Issues.
Techimmune
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q2 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2023 | $20K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$80K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Health & Human Services, Dept of (HHS)3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $80K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/19for Q4 2023 | Forbes-Tate | $30K |
| 24/01/16for Q4 2023 | Forbes-Tate | $30K |
| 23/10/17for Q3 2023 | Forbes-Tate | $30K |
| 23/07/16for Q2 2023 | Forbes-Tate | $20K |
| 23/06/07for Q2 2023 | Forbes-Tate | Under $5,000 |